Pfizer Rezulin Liability Settlements Not Clouding Financial Outlook, Firm Says
Executive Summary
Three recent Rezulin product liability settlements have not altered Pfizer's position that pending cases will not have a material effect on the firm's financial position
You may also be interested in...
Rezulin class action
Pfizer Rezulin class certification petition denied by Manhattan federal Judge Lewis Kaplan in Sept. 12 decision. Petition consolidated litigation from more than 4,000 Rezulin (troglitazone) patients. The diabetes drug was withdrawn from the market in March 2000, following 90 cases of acute liver damage, including 63 deaths. Class actions in West Virginia and California also have been denied (1"The Pink Sheet" Jan. 7, p. 19)...
Rezulin class action
Pfizer Rezulin class certification petition denied by Manhattan federal Judge Lewis Kaplan in Sept. 12 decision. Petition consolidated litigation from more than 4,000 Rezulin (troglitazone) patients. The diabetes drug was withdrawn from the market in March 2000, following 90 cases of acute liver damage, including 63 deaths. Class actions in West Virginia and California also have been denied (1"The Pink Sheet" Jan. 7, p. 19)...
Avandia, Actos To Accelerate Market Growth With Rezulin's Withdrawal
The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.